Showing 4091-4100 of 8895 results for "".
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog
- IPC Comorbidities Symposium Covers Depression, Obesity, and Morehttps://practicaldermatology.com/news/IPC-Comorbidities-Symposium-Covers-Depression-Obesity-More/2471517/Comorbidities of psoriasis were the focus of the International Psoriasis Council’s meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “Syposium: Preventing Comorbig Disease in Psoriasis” started with presentations on depression and card
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre
- Pilot Study Suggests Selumetinib's Potential for Cutaneous Neurofibromashttps://practicaldermatology.com/news/pilot-study-suggests-selumetinibs-potential-for-cutaneous-neurofibromas/2471373/A new nonrandomized pilot trial suggested the MEK inhibitor selumetinib was associated with a reduction in the size of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). These study, published as a brief rep
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- Study: Mohs Lowers Local Recurrence in Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/study-mohs-lowers-local-recurrence-in-cutaneous-squamous-cell-carcinoma/2471328/New research published in JAMA Dermatology suggested that Mohs micrographic surgery (MMS) was associated with a lower local recurrence rate for high-stage cutaneous squamous cell carcinoma (cSCC). The retrospective coho
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr